Email
RSS14/11/08 - 13:31 ... source : Jetix Europe
14/11/08 - 09:03 ... source : Research In Motion
... In Motion (RIM) (Nasdaq: RIMM; TSX: RIM) today launched the BlackBerry® Bold™ smartphone in Sweden. The BlackBerry Bold smartphone offers business professionals and power users unprecedented functionality and performance in an intuitive and stylish design. ...
14/11/08 - 08:45 ... source : Research In Motion - RIM
... In Motion (RIM) (Nasdaq: RIMM; TSX: RIM) today launched the BlackBerry® Bold™ smartphone in Sweden. The BlackBerry Bold smartphone offers business professionals and power users unprecedented functionality and performance in an intuitive and stylish design. ...
14/11/08 - 02:46 ... source : Internet Society - ISOC
... and CEO, Lynn St.Amour will this week join prominent European parliamentarians as well as key European decision makers and business leaders to discuss future directions for the Internet. Ms St.Amour is a keynote speaker at ...
13/11/08 - 19:04 ... source : Johnson & Johnson
13/11/08 - 17:02 ... source : European University Association - EUA
13/11/08 - 15:14 ... source : Jetix Europe
... was in line with management's expectations and the guidance given at the interim results "¢ The decline in revenue was primarily due to the effects of a limited number of previously announced deals, combined with ...
13/11/08 - 15:14 ... source : Jetix Europe
... was in line with management's expectations and the guidance given at the interim results "¢ The decline in revenue was primarily due to the effects of a limited number of previously announced deals, combined with ...
13/11/08 - 08:44 ... source : AstraZeneca
... fumarate extended release tablets) and SEROQUEL (quetiapine fumarate) have been approved under the European Mutual Recognition Procedure (MRP) for new indications in bipolar disorder. SEROQUEL XR and SEROQUEL have been approved for the treatment of ...
13/11/08 - 07:02 ... source : Daiichi Sankyo
... today that its German affiliate received marketing approval for SEVIKAR® a new fixed dose combination treatment for essential hypertension, a condition that significantly contributes to the estimated annual € 192 billion healthcare cost of cardiovascular ...
